128 related articles for article (PubMed ID: 22783423)
1. Amyloid precursor protein as a potential marker of malignancy and prognosis in papillary thyroid carcinoma.
Yang Z; Fan Y; Deng Z; Wu B; Zheng Q
Oncol Lett; 2012 Jun; 3(6):1227-1230. PubMed ID: 22783423
[TBL] [Abstract][Full Text] [Related]
2. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
3. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
4. [Clinicopathological significance of Golgi phosphoprotein 3 expression in papillary thyroid carcinoma].
Huang DH; Jin L; Xie WW; Lin Q; Chen X
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2831-2835. PubMed ID: 31550811
[No Abstract] [Full Text] [Related]
5. Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.
Kim HS; Lee JJ; Do SI; Kim K; Do IG; Kim DH; Chae SW; Sohn JH
Int J Clin Exp Pathol; 2015; 8(5):5695-701. PubMed ID: 26191283
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of FOXE1 in papillary thyroid carcinoma.
Fan Y; Ding Z; Yang Z; Deng X; Kang J; Wu B; Zheng Q
Mol Med Rep; 2013 Jul; 8(1):123-7. PubMed ID: 23715628
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
8. Expression of ANGPTL2 and its impact on papillary thyroid cancer.
Yang L; Sun R; Wang Y; Fu Y; Zhang Y; Zheng Z; Ji Z; Zhao D
Cancer Cell Int; 2019; 19():204. PubMed ID: 31384179
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
10. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
[TBL] [Abstract][Full Text] [Related]
11. Correlations of ultrasound and pathological features of thyroid carcinoma with TC-1 mRNA and protein expression.
Zhang CL; Geng CH; Jian JJ; He M; Zhao HW; Li HY
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3440-3446. PubMed ID: 31081098
[TBL] [Abstract][Full Text] [Related]
12. [High aldehyde dehydrogenase 1A1 (ALDH1A1) expression correlated with risk of lymph node metastasis in papillary thyroid carcinoma].
Yue C; Zhao X; Tian C; Jin Y; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):490-4. PubMed ID: 26705040
[TBL] [Abstract][Full Text] [Related]
13. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
14. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
15. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
16. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.
Guarino V; Faviana P; Salvatore G; Castellone MD; Cirafici AM; De Falco V; Celetti A; Giannini R; Basolo F; Melillo RM; Santoro M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5270-8. PubMed ID: 15998773
[TBL] [Abstract][Full Text] [Related]
18. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
19. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
20. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
